Compare FFBC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFBC | RARE |
|---|---|---|
| Founded | 1863 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | N/A | 2014 |
| Metric | FFBC | RARE |
|---|---|---|
| Price | $30.19 | $23.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $29.50 | ★ $73.11 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 01-28-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 10.83 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $861,817,000.00 | $630,598,000.00 |
| Revenue This Year | $26.94 | $20.38 |
| Revenue Next Year | $4.48 | $19.02 |
| P/E Ratio | $11.45 | ★ N/A |
| Revenue Growth | 13.99 | ★ 20.63 |
| 52 Week Low | $21.10 | $18.41 |
| 52 Week High | $31.38 | $46.27 |
| Indicator | FFBC | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 41.78 |
| Support Level | $29.26 | $23.76 |
| Resistance Level | $31.38 | $24.68 |
| Average True Range (ATR) | 0.97 | 1.06 |
| MACD | 0.15 | 0.23 |
| Stochastic Oscillator | 75.77 | 23.36 |
First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and noninterest-bearing accounts, time deposits and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.